Status:
COMPLETED
Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the quality of the RNA and the reproducibility of gene expression profiling from liver tissue samples obtained by fine needle aspiration.
Eligibility Criteria
Inclusion
- Patient has chronic hepatitis C (Genotype 1)
- Patient has the ability to avoid use of anticoagulants, nonsteroidal anti-inflammatory drugs and aspirin for at least 5 days before the liver biopsy
Exclusion
- Patient has received any approved or investigational drugs for the treatment of hepatitis C in the six months before the liver biopsy
- Patient has HIV or Hepatitis B virus
- Patient has been diagnosed with liver cancer
- Patient has evidence of cirrhosis on any previous liver biopsy
- Patient has confirmed alcohol abuse in the last 12 months
- Patient has participated in any investigational drug study within 90 days before the current study
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00828269
Start Date
April 1 2009
End Date
March 1 2010
Last Update
April 22 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.